CannapharmaRX Updates on Alberta Facility Progress and International Export Strategy
CannaPharmaRX (OTC PINK:CPMD) provides updates on its Alberta cannabis facility operations and international expansion plans. The facility features 10 growing rooms, each producing approximately 130kg per harvest cycle (95kg premium flowers, 35kg trim). Currently operating four rooms with a fifth planned for December, the company projects monthly production of 210kg flowers and 77kg trim. Products are priced at 1.9-2.2 CAD/gram for flowers and 0.1-0.2 CAD/gram for trim, targeting monthly revenue of 430,000 CAD. International expansion includes planned shipments to Israel and potential European market entry. The company plans to launch branded products in late 2025, aiming for prices up to 3 CAD/gram.
CannaPharmaRX (OTC PINK:CPMD) fornisce aggiornamenti sulle operazioni della sua struttura cannabis in Alberta e sui piani di espansione internazionale. La struttura dispone di 10 stanze di coltivazione, ciascuna in grado di produrre circa 130 kg per ciclo di raccolta (95 kg di fiori di alta qualità, 35 kg di scarti). Attualmente, sono operative quattro stanze con una quinta prevista per dicembre; l'azienda prevede una produzione mensile di 210 kg di fiori e 77 kg di scarti. I prodotti sono prezzo tra 1,9 e 2,2 CAD/grammo per i fiori e tra 0,1 e 0,2 CAD/grammo per gli scarti, puntando a un fatturato mensile di 430.000 CAD. L'espansione internazionale include spedizioni pianificate verso Israele e un potenziale ingresso nel mercato europeo. L'azienda prevede di lanciare prodotti a marchio entro la fine del 2025, con prezzi che potrebbero raggiungere i 3 CAD/grammo.
CannaPharmaRX (OTC PINK:CPMD) proporciona actualizaciones sobre las operaciones de su instalación de cannabis en Alberta y sus planes de expansión internacional. La instalación cuenta con 10 habitaciones de cultivo, cada una produciendo aproximadamente 130 kg por ciclo de cosecha (95 kg de flores premium, 35 kg de recortes). Actualmente opera cuatro habitaciones, con una quinta planeada para diciembre; la compañía proyecta una producción mensual de 210 kg de flores y 77 kg de recortes. Los productos tienen un precio de 1.9-2.2 CAD/gramo para flores y 0.1-0.2 CAD/gramo para recortes, con un objetivo de ingresos mensuales de 430,000 CAD. La expansión internacional incluye envíos planeados a Israel y una posible entrada en el mercado europeo. La empresa planea lanzar productos de marca a finales de 2025, con precios de hasta 3 CAD/gramo.
CannaPharmaRX (OTC PINK:CPMD)는 알버타에 있는 대마초 시설 운영 및 국제 확장 계획에 대한 업데이트를 제공합니다. 이 시설은 10개 재배실을 갖추고 있으며, 각 재배실은 수확 주기당 약 130kg를 생산합니다 (프리미엄 꽃 95kg, 다듬기 35kg). 현재 4개의 재배실이 운영 중이며, 12월에는 5번째 재배실이 계획되어 있습니다. 회사는 매월 210kg의 꽃과 77kg의 다듬기 생산을 예상하고 있습니다. 제품은 꽃의 경우 1.9-2.2 CAD/그램, 다듬기의 경우 0.1-0.2 CAD/그램으로 가격 책정되며, 월간 수익 목표는 430,000 CAD입니다. 국제 확장에는 이스라엘로의 수출과 유럽 시장 진출 가능성이 포함되어 있습니다. 회사는 2025년 말에 브랜드 제품을 출시할 계획이며, 가격은 최대 3 CAD/그램에 이를 것으로 예상하고 있습니다.
CannaPharmaRX (OTC PINK:CPMD) fournit des mises à jour sur les opérations de son installation de cannabis en Alberta et sur ses plans d'expansion internationale. L'installation comprend 10 salles de culture, chacune produisant environ 130 kg par cycle de récolte (95 kg de fleurs de qualité supérieure, 35 kg de déchets). Actuellement, quatre salles sont en fonctionnement avec une cinquième prévue pour décembre; la société prévoit une production mensuelle de 210 kg de fleurs et 77 kg de déchets. Les produits sont tarifés entre 1,9 et 2,2 CAD/gramme pour les fleurs et entre 0,1 et 0,2 CAD/gramme pour les déchets, visant un revenu mensuel de 430 000 CAD. L'expansion internationale comprend des envois prévus vers Israël et une éventuelle entrée sur le marché européen. L'entreprise prévoit de lancer des produits de marque fin 2025, visant des prix pouvant atteindre 3 CAD/gramme.
CannaPharmaRX (OTC PINK:CPMD) gibt Updates zu seinen Betriebsabläufen in der Cannabis-Anlage in Alberta und zu den internationalen Expansionsplänen. Die Anlage umfasst 10 Anbauräume, wobei jeder Raum etwa 130 kg pro Erntezyklus produziert (95 kg Premiumblüten, 35 kg Trimm). Derzeit werden vier Räume betrieben, mit einem fünften Raum, der für Dezember geplant ist; das Unternehmen rechnet mit einer monatlichen Produktion von 210 kg Blüten und 77 kg Trimm. Die Produkte sind mit Preisen von 1,9-2,2 CAD/Gramm für Blüten und 0,1-0,2 CAD/Gramm für Trimm versehen, mit einem angestrebten monatlichen Umsatz von 430.000 CAD. Die internationale Expansion umfasst geplante Sendungen nach Israel und einen möglichen Eintritt in den europäischen Markt. Das Unternehmen plant, Ende 2025 markenrechtliche Produkte einzuführen, mit Preisen von bis zu 3 CAD/Gramm.
- Current production capacity of 210kg flowers and 77kg trim monthly
- Secured orders for entire yield, projecting 430,000 CAD monthly revenue
- Planned expansion to international markets with confirmed shipments to Israel
- Potential price increase to 3 CAD/gram with branded products launch in 2025
- Additional revenue stream through 5-10% commission on third-party farm exports
- Operating at partial capacity with only 4 out of 10 growing rooms active
- Current low-margin pricing strategy (1.9-2.2 CAD/gram)
- Outstanding cease trade orders from BCSC requiring resolution
- Existing short and long-term debt obligations requiring strategic management
- Lack of permanent CEO potentially impacting strategic execution
CALGARY, AB / ACCESSWIRE / December 3, 2024 / CannaPharmaRX, Inc. (OTC PINK:CPMD), a future leader in cannabis cultivation, is steadily advancing its position in high-efficiency cannabis production. The Company is excited to share its latest updates with shareholders and prospective investors, highlighting its substantial progress, current operations, and future growth plans.
Advanced Production Facility in Alberta
CannaPharmaRX's advanced facility in Alberta houses 10 growing rooms designed for maximum efficiency and yield. Each room produces an average harvest of 130 kilograms, comprising approximately 95 kilograms of premium flowers and 35 kilograms of trim products, all within an 8-10-week harvest cycle.
Currently, the Company operates four active growing rooms and plans to add another in December, enabling a bi-weekly harvest schedule. This operational strategy translates to an estimated monthly production of 210 kilograms of flower and 77 kilograms of trim, ensuring a steady supply for its growing customer base.
Revenue Projections
The Company's non-branded cannabis products are competitively priced at 1.9 - 2.2 CAD per gram for flowers and 0.1 - 0.2 CAD per gram for trim. With strong demand, CannaPharmaRX is projected to generate approximately 430,000 CAD in monthly revenue, with current orders accounting for the entire yield. Looking ahead to late 2025, the planned launch of branded cannabis products is expected to further drive profitability, with flower prices projected to reach up to 3 CAD per gram.
Global Export Initiatives
CannaPharmaRX is making progress in international markets, with upcoming shipments planned for:
December 2024: 245.7 kilograms to Israel
January 2025: Approximately 385 kilograms
Additionally, the Company is leveraging partnerships with third-party farms, enabling the shipment of 72 kilograms of cannabis to customers in Israel in exchange for a 5
To expand its global footprint, CannaPharmaRX is conducting a feasibility study targeting exports to Europe, with a particular focus on Germany.
Growth Plans for 2025
To optimize production and meet increasing demand, CannaPharmaRX is exploring the construction of an additional drying room. This development would support a one-week harvest cycle across all 10 growing rooms. The Company also plans to launch its branded cannabis products in 2025, aiming to strengthen its position as a premium provider.
Short and long-term liabilities
A strategic plan for 2025 is being developed to reduce long-term debt and strengthen the company's financial position and to keep current in its short-term obligations.
New CEO
To drive its vision of international expansion and innovation, CannaPharmaRX is actively seeking a CEO with global expertise. This new leadership role is key to advancing the company's goals and scaling operations internationally.
CTO
In compliance with Canadian regulations, CannaPharmaRX is actively engaging with local authorities to lift the cease trade orders from BCSC.
Forward-Looking Statements. This release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by the use of forward-looking words such as "expect," "expectation," "believe," "anticipate," "may," "could," "intend," "belief," "plan," "estimate," "target," "predict," "likely," "seek," "project," "model," "ongoing," "will," "should," "forecast," "outlook" or similar terminology. These statements are based on and reflect our current expectations, estimates, assumptions and/ or projections, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements are neither predictions nor guarantees of future events, circumstances or performance and are inherently subject to known and unknown risks, uncertainties and assumptions that could cause our actual results to differ materially from those indicated by those statements. There can be no assurance that our expectations, estimates, assumptions and/or projections, including with respect to the future earnings and performance or capital structure of CannaPharmaRX, will prove to be correct or that any of our expectations, estimates or projections will be achieved. The forward-looking statements included in this release are only made as of the date of this announcement and we disclaim any obligation to publicly update any forward-looking statement to reflect subsequent events or circumstances. You should consult our filings with the Securities and Exchange Commission and on SEDAR (including the information set forth under the captions "Risk Factors" and "Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q) for additional detail about factors that could affect our financial and other results.
Contact:
Company: CannapharmaRx
Name: Constanitne Nkafu
Website: https://cannapharmarx.com
Phone: 403-637-0420
Mail: info@cannapharmarx.com
SOURCE: CannaPharmaRx
View the original press release on accesswire.com
FAQ
What is the current production capacity of CannaPharmaRX (CPMD) Alberta facility?
What are the current selling prices for CPMD's cannabis products?
When will CPMD begin international shipments to Israel?
What are CPMD's revenue projections from current operations?
